The ability of both the Drd3 gene deletion and buspirone treatment and, to a lesser extent, Htr1a gene ablation, to reduce inflammation in microglia suggests that buspirone holds the potential to be repurposed as an effective anti-inflammatory agent to treat those neurological diseases associated with chronic neuroinflammation, including Parkinson’s disease. This evidence concerns the gene HTR1A and Parkinson disease.